Delta Plus variant: Centre writes to Maharashtra, MP, Kerala to take up immediate containment measures

Photo for representational purpose

The Union Health Ministry wrote to the chief secretaries of Maharashtra, Madhya Pradesh and Kerala and requested them to take up immediate containment measures as cases of Delta Plus variant were found in these three states.

Health Secretary Rajesh Bhushan, in the letter, requested the chief secretaries to take up immediate containment measures in these districts and clusters including preventing crowds and intermingling of people, widespread testing, prompt tracing as well as vaccine coverage on a priority basis.

Bhushan said it is intimated that Delta Plus variant has been found in Bhopal and Shivpuri districts of Madhya Pradesh, Ratnagiri and Jalgaon districts of Maharashtra, and Palakkad and Pathanamthitta districts of Kerala.

Also Read: Delta Plus still 'variant of interest', 40 cases reported in India so far: Govt sources

"The Public Health Response, in this case, while broadly remaining the same, has to become more focused and stringent. Thus, you are requested to take up immediate containment measures in these districts and clusters including preventing crowds and intermingling of people, widespread testing, prompt tracing as well as vaccine coverage on a priority basis," read the letter.

"You are requested to ensure that adequate samples of positive persons are sent to the designated laboratories of INSACOG promptly so that the clinical epidemiological correlations can be made," it said.

The Union Health Ministry on Wednesday informed that the Delta Plus variant was observed sporadically in Maharashtra, Kerala and Madhya Pradesh with around 40 cases identified so far, and added that there is no significant increase in its prevalence.

These states have been advised for strengthening surveillance and appropriate public health measures.

"As of now among the samples sequenced (45000+) in India, this variant has been observed sporadically in Maharashtra, Kerala & Madhya Pradesh, with around 40 cases identified so far and no significant increase in prevalence," Union Health Ministry said in a statement.

The statement notes, all Delta sub-lineages are treated as a VOC (Variant of Concern), although properties of AY.1 are still being investigated. "Currently, the variant frequency of AY.1 is low in India. Cases with AY.1 have been mostly reported from nine countries of Europe, Asia and America," it said.

The retrospective analysis of samples revealed the first occurrence of this lineage from a sample collected from Maharashtra (sample collection date -April 5, 2021).

"As of 18th June, 205 sequences of AY.1 lineage was detected worldwide, with USA and UK having over half the known cases," the Union health ministry noted.

The ministry said the role of AY.1's role in immune escape, disease severity or increased transmissibility etc. is under continued surveillance.

"Currently the number of such Delta plus variants in India are only few but the distribution / detection in various States during past two+ months indicate that the B.1.617.2.1 (AY.1) is already present in some States and States may need to enhance their public health response by focusing on surveillance, enhanced testing, quick contact-tracing and priority vaccination in defined geographies where AY.1 has been detected," it said.

Following the advisory, Maharashtra Health Minister Rajesh Tope said, "I have directed officials that the Delta Plus variant cases should be monitored closely. Information about these cases should be collected and recorded for study. We are taking 100 samples from every district."

INSACOG, a consortium of 28 laboratories of the Ministry of Health and Family Welfare, Department of Biotechnology, Indian Council of Medical Research (ICMR), and Council of Scientific and Industrial Research (CSIR), has informed that the Delta Plus Variant, currently a Variant of Concern (VOC), has the following characteristics: Increased transmissibility; Stronger binding to receptors of lung cells and Potential reduction in monoclonal antibody response.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.